Cold exposure and tirzepatide: mouse study

A study published 10 September 2026 in the American Journal of Physiology, Regulatory, Integrative and Comparative Physiology reports that repeated cold exposure did not add to the weight-loss effect of tirzepatide in obese mice^[1]. Bellucci and colleagues at the University of British Columbia and BC Children's Hospital Research Institute set out to test whether pairing a cold protocol with tirzepatide could push weight loss further than either approach alone. The answer, in their mouse model, was no.

What the researchers did

Male and female C57BL/6J mice were fed a high-fat diet for 8 weeks to induce obesity, then split into groups receiving tirzepatide (10 nmol/kg) or a vehicle control^[1]. Within those groups, some animals also underwent intermittent cold exposure, described in the paper as 4 degrees Celsius for one hour a day, five days a week, for three weeks. The researchers tracked body weight, body composition, food intake, energy expenditure, and measures of glucose homeostasis across the groups.

What the study found

Tirzepatide on its own reduced body weight, food intake, and adiposity in both male and female mice, consistent with what the drug does in other rodent and human studies^[1]. Cold exposure on its own acutely raised energy expenditure and improved glucose handling, and it did this independently of any change in body weight. But when the two were combined, the cold protocol did not produce extra weight loss on top of what tirzepatide achieved alone. The authors describe the combination as producing "complementary, but not necessarily additive" improvements in metabolic health, not a stacked or amplified effect.

That distinction matters. Complementary means the two interventions can improve different aspects of metabolic health side by side, such as glucose control from cold exposure and appetite suppression from tirzepatide. Additive would mean combining them produces more total weight loss than either alone. The researchers found the first, not the second, for body weight specifically.

Why this is a mouse study, not a human one

Everything above happened in laboratory mice, not people. That distinction is not a footnote, it is the central fact that should shape how anyone reads this paper. Rodent thermogenesis biology differs from human biology in ways that matter for exactly this question. Mice have a much higher ratio of brown fat to body mass than adult humans, and brown fat is the tissue most responsible for cold-induced calorie burning. A cold exposure protocol that meaningfully activates thermogenesis in a mouse may barely register in an adult human, whose brown fat deposits are smaller, more variable between individuals, and less active outside of specific conditions.

Dosing is another gap. The mice in this study received tirzepatide at 10 nmol/kg, a research dose calibrated to rodent pharmacokinetics. That number has no direct translation to the milligram doses used in human tirzepatide prescriptions such as Mounjaro or Zepbound. Body-surface-area scaling, metabolism speed, and drug half-life all differ between mice and people, so a finding tied to a specific rodent dose and a specific three-week cold schedule cannot be read as a statement about what happens at any particular human dose or duration.

Mouse obesity models are also built differently than human obesity. Eight weeks of high-fat feeding in a genetically uniform lab strain produces a fast, controlled form of diet-induced obesity. Human obesity develops over years, involves far more genetic and environmental variation, and coexists with conditions like insulin resistance and cardiovascular risk factors that this mouse model does not need to replicate. None of that makes the mouse data useless. It means the mouse data answers a narrower question than it might appear to at first glance, and that question is about mechanism, not about what a person combining cold exposure with tirzepatide should expect.

What this means for the cold exposure trend

Cold exposure, whether through cold plunges, ice baths, or cryotherapy, has become a popular add-on among people using tirzepatide and other GLP-1 class drugs, often on the theory that boosting energy expenditure through cold will accelerate weight loss on top of the medication. This mouse study is one of the first controlled tests of that exact combination, and its result runs against the popular theory: in mice, adding a structured cold protocol did not produce extra weight loss beyond what tirzepatide delivered by itself.

That is a useful data point, but it is not a verdict on humans. No human trial has tested whether cold exposure protocols change weight outcomes for people on tirzepatide, and this study was not designed to answer that question. Researchers observed a specific result in a specific mouse model under a specific cold and dosing schedule. Extending that finding to recommend for or against cold exposure in human tirzepatide users would be reading more into the data than the data supports.

What we don't yet know

The paper does not report whether the null result on weight would hold at different tirzepatide doses, longer cold exposure durations, or in older or non-obese animals. It does not address whether cold exposure changes side-effect tolerability, appetite signalling pathways, or long-term weight maintenance after stopping the drug. And because this is a single animal study, its finding needs replication before anyone treats "complementary, not additive" as a settled description of how cold exposure and tirzepatide interact, even in mice.

A negative result worth keeping in view

This is an animal study reporting a negative result for a popular idea: that cold exposure might amplify tirzepatide's weight-loss effect. In obese mice, it did not. The finding adds useful mechanistic detail about how cold exposure and an incretin-based drug affect metabolism through different pathways, but it says nothing directly about human tirzepatide users, and it is not a basis for adopting or dropping any cold exposure practice. Anyone with questions about combining lifestyle interventions with a prescribed medication should raise them with the clinician managing that prescription, not a mouse paper.